Paricalcitol
Paricalcitol is a vitamin D analog used to prevent and treat secondary hyperparathyroidism (overactive parathyroid glands) in people with chronic kidney disease, as capsules or as an injection given during dialysis.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 11 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Paricalcitol (Zemplar) is a man-made active vitamin D that lowers parathyroid hormone (PTH) in chronic kidney disease, where damaged kidneys struggle to activate vitamin D and the parathyroid glands overwork; a familiar kidney-specialist drug since about 1998, it is available generically. Most people tolerate it well, and the side effects they notice most are mild stomach upset such as nausea or diarrhea. The real thing to watch for is high blood calcium, so report tiredness, foggy thinking, constipation, unusual thirst or frequent urination promptly. Regular blood tests for calcium and PTH guide every dose change, because pushing PTH too low can weaken bone.
Clinical pearls
- Thiazide water pills, calcium supplements and extra vitamin D all push calcium higher, so clear them with your kidney team first.
- If you take digoxin, a digitalis heart medicine, high calcium from paricalcitol makes digoxin toxicity more likely.
- Avoid grapefruit juice, and flag new prescriptions like clarithromycin, ketoconazole or ritonavir, which can raise paricalcitol levels.
- On the three-times-weekly capsule schedule, never take doses closer together than every other day.
Patient information guide A plain-language walkthrough of Paricalcitol, written from its FDA label.
What Paricalcitol is used for
▾
Paricalcitol is used for secondary hyperparathyroidism linked to chronic kidney disease.
- Capsules (Paricalcitol): adults with CKD Stages 3 and 4.
- Capsules (Paricalcitol): adults with CKD Stage 5 on hemodialysis or peritoneal dialysis.
- Zemplar capsules: also labeled for children 10 years and older with these conditions.
- Injection (Paricalcitol and Zemplar): patients 5 years and older with CKD on dialysis.
How Paricalcitol works
▾
Paricalcitol is a synthetic vitamin D analog. It binds to the vitamin D receptor and activates vitamin D pathways. This lowers the making and release of PTH.
In kidney disease, vitamin D activation drops and PTH rises, which can disturb calcium, phosphorus and bone health.
Paricalcitol dosage
▾
Capsules are taken by mouth, once daily or three times a week depending on CKD stage and your prescriber's plan. The injection is given into a vein through the dialysis access during dialysis.
- Food does not change how much capsule drug is absorbed, but it delays the peak by about 2 hours.
- Doses are adjusted using PTH, calcium and phosphorus blood tests.
Follow your prescriber and label for your schedule.
Dosing details from the FDA-approved label
From the Paricalcitol prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Oral capsule: CKD Stages 3 and 4, adults, baseline iPTH ≤ 500 pg/mL
- 1 mcg orally daily or 2 mcg three times a week
- Titrate at 2 to 4 week intervals: if iPTH is the same, increased or decreased by less than 30% relative to baseline, increase dose by 1 mcg daily or 2 mcg three times a week
- If decreased by ≥ 30% and ≤ 60%, maintain dose
- If decreased by > 60% or iPTH < 60 pg/mL, decrease dose by 1 mcg daily or 2 mcg three tim
- Three times a week dosing not more frequently than every other day
- Oral capsule: CKD Stages 3 and 4, adults, baseline iPTH > 500 pg/mL
- 2 mcg orally daily or 4 mcg three times a week
- Titrate as for baseline iPTH ≤ 500 pg/mL
- Three times a week dosing not more frequently than every other day
- Oral capsule: CKD Stages 3 and 4, pediatric ages 10 to 16 years
- 1 mcg orally three times a week
- Increase each dose by 1 mcg three times a week every 4 weeks or decrease each dose by 1 mcg three times a week at any time based on iPTH, serum calcium and phosphorus levels
- Not more frequently than every other day; may be stopped if reduction is needed while on 1 mcg three times per week
- Oral capsule: CKD Stage 5, adults
- Dose (micrograms) = baseline iPTH (pg/mL) divided by 80, orally three times a week
- Titrate with dose (micrograms) = most recent iPTH divided by 80, adjusted for serum calcium and phosphorus
- If serum calcium is elevated, decrease dose by 2 to 4 micrograms
- Treat only after baseline serum calcium is 9.5 mg/dL or lower; not more frequently than every other day
- Oral capsule: CKD Stage 5, pediatric ages 10 to 16 years
- Dose (micrograms) = baseline iPTH (pg/mL) divided by 120, orally three times a week (round down to nearest whole number)
- Every 4 weeks increase each dose by 1 mcg or at any time decrease each dose by 2 mcg
- Not more frequently than every other day; may be stopped if reduction is needed while on 2 mcg or 1 mcg three times per week
- Intravenous injection: adults
- Initiate as IV bolus 0.04 mcg/kg to 0.1 mcg/kg (2.8 mcg to 7 mcg) no more frequently than every other day at any time during dialysis
- Titrate by intact PTH (increase by 2 mcg to 4 mcg every 2 to 4 weeks if above target and PTH increased or decreased by less than 30%)
- Maximum: 0.24 mcg/kg maximum daily adult dose
- Ensure serum calcium is not above upper limit of normal before starting; suspend or decrease dose if intact PTH is persistently low or calcium is consistently above normal
- Intravenous injection: pediatric
- IV bolus 0.04 mcg/kg if baseline intact PTH is less than 500 pg/mL, or 0.08 mcg/kg if baseline intact PTH is 500 pg/mL or greater
- Monitor serum calcium frequently (e.g., twice weekly) and intact PTH every 2 to 4 weeks
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Initial Dosage: CKD Stages 3 and 4 ( 2.1 , 2.3 ) Adult: Baseline iPTH ≤ 500 pg/mL 1 mcg orally daily or 2 mcg three times a week* Adult: Baseline iPTH > 500 pg/mL 2 mcg orally daily or 4 mcg three times a week* Pediatric: Ages 10 to 16 years 1 mcg orally three times a week* Dose Titration: CKD Stages 3 and 4 ( 2.1 , 2.3 ) Adult: iPTH same, increased or decreased by < 30% relative to baseline Increase dose by 1 mcg daily or 2 mcg three times a week* Adult: iPTH decreased by ≥ 30% and ≤ 60% relative to baseline Maintain dose Adult: iPTH decreased by > 60% or iPTH < 60 pg/mL relative to baseline Decrease dose by 1 mcg daily or 2 mcg three times a week* Pediatric: Ages 10 to 16 years Increase each dose by 1 mcg three times a week every 4 weeks or decrease each dose by 1 mcg three times a week at any time based on iPTH, serum calcium and phosphorus levels.* * Not more frequently than every other day when dosing three times a week. Initial Dosage: CKD Stage 5 ( 2.2 , 2.3 ) Adult Dose (micrograms) = baseline iPTH (pg/mL) divided by 80. Administer dose orally three times a week.* Pediatric: Ages 10 to 16 years Dose (micrograms) = baseline iPTH (pg/mL) divided by 120. Administer dose orally three times a week.* Dose Titration: CKD Stage 5 ( 2.2 , 2.3 ) Adult Dose in micrograms is based on most recent iPTH (pg/mL) divided by 80 with adjustments based on serum calcium and phosphorous levels. Dose three times a week.* Pediatric: Ages 10 to 16 years Increase each dose by 1 mcg three times a week every 4 weeks or decrease each dose by 2 mcg three times a week at any time based on iPTH, serum calcium and phosphorus levels.* * Not more frequently than every other day. CKD Stage 5: To avoid hypercalcemia only treat patients after their baseline serum calcium has been reduced to 9.5 mg/dL or lower ( 2.2 ). 2.1 Chronic Kidney Disease Stages 3 and 4 in Adults Administer paricalcitol capsules orally once daily or three times a week [see Clinical Studies (14.1) ]. When dosing three times weekly, do not administer more frequently than every other day. Initial Dose Table 1.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Paricalcitol side effects
▾
The most common side effects reported include:
Common side effects
- Diarrhea
- Nausea and vomiting
- Dizziness
- High blood pressure
- Swelling (edema)
- Cold-like symptoms (nasopharyngitis)
- Hypersensitivity (allergic-type) reactions
When to get medical help
- Symptoms of high calcium: tiredness, trouble thinking clearly, loss of appetite, nausea, vomiting, constipation, increased thirst, increased urination, weight loss
- Signs of a severe allergic reaction, such as swelling of the face, lips or throat (angioedema) or hives
- Irregular heartbeat or seizures, which can occur with severe high calcium and may need emergency care
- Signs of digitalis toxicity if you take a digitalis heart medicine
Call your doctor about symptoms of high calcium, and get urgent help for facial or throat swelling or hives.
Paricalcitol warnings and precautions
▾
- High calcium can cause irregular heartbeat and seizures. Severe cases may need emergency care.
- Long-term high calcium can cause calcium deposits in blood vessels and soft tissues.
- Too much calcium and phosphate intake with vitamin D compounds can cause high calcium or phosphate in urine or blood.
- Over-lowering PTH can cause adynamic bone disease and fractures.
- High calcium raises the risk of digitalis toxicity.
Paricalcitol interactions
▾
These can change calcium levels or paricalcitol exposure:
- High-dose calcium products and other vitamin D compounds: raise risk of high calcium.
- Thiazide diuretics: raise calcium by reducing its loss in urine.
- Digitalis compounds: high calcium raises toxicity risk.
- Strong CYP3A inhibitors (such as ketoconazole, clarithromycin, grapefruit juice): increase paricalcitol exposure.
Interactions listed in the FDA-approved label
From the Paricalcitol prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Calcium-containing products, other vitamin D compounds or thiazide diuretics: High doses of calcium-containing preparations or other vitamin D compounds may increase the risk of hypercalcemia, and thiazide diuretics induce hypercalcemia by reducing urinary calcium excretion. Monitor calcium more frequently and adjust Paricalcitol Injection dose as needed.
- Digitalis compounds: Paricalcitol can cause hypercalcemia which can potentiate the risk of digitalis toxicity. Monitor for signs and symptoms of digitalis toxicity and increase frequency of serum calcium monitoring when initiating or adjusting the dose.
- Strong CYP3A inhibitors (clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, voriconazole): Paricalcitol is partially metabolized by CYP3A, and its exposure will increase with strong CYP3A inhibitors. If a patient initiates or discontinues a strong CYP3A4 inhibitor, dose adjustment may be necessary; monitor intact PTH and serum calcium closely.
Read the label’s full interactions text
7 DRUG INTERACTIONS Table 6 shows the clinically significant drug interactions with paricalcitol capsules. Table 6: Clinically Significant Drug Interactions with Paricalcitol CYP3A Inhibitors Clinical Impact Paricalcitol is partially metabolized by CYP3A. Hence, exposure of paricalcitol will increase upon co-administration with strong CYP3A inhibitors such as but not limited to: boceprevir, clarithromycin, conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole. Intervention Dose adjustment of paricalcitol capsules may be necessary. Monitor closely for iPTH and serum calcium concentrations, if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor. Cholestyramine Clinical Impact Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of paricalcitol. Intervention Recommend to take paricalcitol capsules at least 1 hour before or 4 to 6 hours after taking cholestyramine (or at as great an interval as possible) to avoid impeding absorption of paricalcitol. Mineral Oil Clinical Impact Mineral oil or other substances that may affect absorption of fat may influence the absorption of paricalcitol. Intervention Recommend to take paricalcitol capsules at least 1 hour before or 4 to 6 hours after taking mineral oil (or at as great an interval as possible) to avoid affecting absorption of paricalcitol. • Strong CYP3A inhibitors (e.g. ketoconazole) will increase the exposure of paricalcitol. Use with caution ( 7 ). • Cholestyramine, Mineral Oil: Intestinal absorption of paricalcitol may be reduced if administered simultaneously with cholestyramine or mineral oil. Take paricalcitol capsules at least 1 hour before or 4 to 6 hours after taking cholestyramine or mineral oil ( 7 ).
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Paricalcitol
▾
- Do not use with high calcium, vitamin D toxicity or known allergy to paricalcitol.
- Breastfeeding is not recommended.
- Human pregnancy data are limited.
- Capsules are not established under age 10, and the injection is not established under age 5.
- Older adults had no overall differences, though some may be more sensitive.
- No dose change is needed for mild or moderate liver impairment. Severe liver impairment has not been studied.
Paricalcitol overdose
▾
Too much paricalcitol can cause high calcium, high calcium in urine, high phosphate and over-suppressed PTH. Treatment is supportive, with monitoring of calcium and heart rhythm, stopping calcium supplements and following a low-calcium diet. Paricalcitol is not significantly removed by dialysis.
What Paricalcitol does in the body
▾
Paricalcitol lowers intact PTH and raises blood calcium and phosphorus in people on hemodialysis or peritoneal dialysis. Lower starting calcium and PTH-based dosing were predicted to lower the chance of high calcium.
How your body processes Paricalcitol
▾
About 72% to 86% of the capsule dose is absorbed. It is heavily bound to proteins in the blood and extensively broken down by the liver and other enzymes. Most leaves in the stool, with some in the urine. The half-life is 4 to 6 hours in healthy adults and 14 to 20 hours in people with CKD.
How to store Paricalcitol
▾
Store paricalcitol capsules at 20°-25°C (68°-77°F) . Protect from light.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Paricalcitol: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Paricalcitol — the kind of thing our pharmacy team would talk through with you at the counter.
What is paricalcitol for?
▾
How do I take it?
▾
What side effects are common?
▾
What symptoms mean my calcium may be too high?
▾
Can I take calcium, vitamin D or other medicines with it?
▾
Is it safe in pregnancy or breastfeeding?
▾
Is Paricalcitol available over the counter?
▾
When was Paricalcitol first available?
▾
Who makes Paricalcitol?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Paricalcitol on HelloPharmacist
Paricalcitol forms and strengths (how it comes)
Paricalcitol is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Paricalcitol inactive ingredients by manufacturer.
Capsule
How this form is used
- Zemplar capsules are used in adults and children 10 years and older for secondary hyperparathyroidism with CKD Stages 3 and 4, and CKD Stage 5 on dialysis.
- Paricalcitol capsules are used in adults for secondary hyperparathyroidism with CKD Stages 3 and 4, and CKD Stage 5 on dialysis.
- Paricalcitol capsules are taken by mouth, once daily or three times a week for CKD Stages 3 and 4.
- Paricalcitol capsules for CKD Stage 5 are taken by mouth three times a week.
- When dosing three times a week, Paricalcitol capsules are not taken more often than every other day.
Injection
How this form is used
- Zemplar injection is used for secondary hyperparathyroidism in patients 5 years and older with CKD on dialysis.
- Paricalcitol injection is used for secondary hyperparathyroidism in patients 5 years and older with CKD on dialysis.
- Zemplar injection is given into a vein through the hemodialysis access at any time during dialysis.
- Paricalcitol injection is given through the hemodialysis access during dialysis, no more often than every other day.
- Serum calcium is checked before starting, and calcium and PTH are monitored after dose changes.
Paricalcitol on the U.S. market: products, makers and brands
How Paricalcitol appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
11 companies list 39 Paricalcitol product records with the FDA, mostly as capsule, injection; the earliest marketing or approval year on record is 1998. Brand names on the directory include Zemplar; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (6) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Paricalcitol is used (Medicaid data)
A general measure of how commonly Paricalcitol is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Paricalcitol is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Paricalcitol prescribed? Of the 1,601 medications we measure, Paricalcitol ranks #480 by Medicaid prescriptions — more than 70% of them.
Utilization by Paricalcitol product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
1 ML paricalcitol 0.005 MG/ML Injection Most dispensed
Summed across the 3 of 13 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1736919
paricalcitol 0.005 MG/ML Injectable Solution
Summed across the 2 of 14 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 200321
1 ML paricalcitol 0.002 MG/ML Injection
Summed across the 3 of 13 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1736931
paricalcitol 0.001 MG Oral Capsule
Summed across the 2 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 577315
paricalcitol 0.002 MG Oral Capsule
Summed across the 2 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 577317
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Paricalcitol, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 12 of 74 listed Paricalcitol NDCs with Medicaid activity.
Compare Paricalcitol products
A representative set of FDA-listed product records for Paricalcitol — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 1 mcg | Oral | AbbVie Inc. | NDA | View NDC → |
| 2 mcg | Oral | AbbVie Inc. | NDA | View NDC → |
| 1 mcg | Oral | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 2 mcg | Oral | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 4 mcg | Oral | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 1 mcg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 2 mcg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 4 mcg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 1 mcg | Oral | Bionpharma Inc. | ANDA | View NDC → |
| 2 mcg | Oral | Bionpharma Inc. | ANDA | View NDC → |
| 4 mcg | Oral | Bionpharma Inc. | ANDA | View NDC → |
| 1 mcg | Oral | Bryant Ranch Prepack × 2 listings | ANDA | View NDC → |
| 2 mcg | Oral | Bryant Ranch Prepack × 2 listings | ANDA | View NDC → |
| 1 mcg | Oral | Dr. Reddy's Laboratories Limited | ANDA | View NDC → |
| 2 mcg | Oral | Dr. Reddy's Laboratories Limited | ANDA | View NDC → |
| 4 mcg | Oral | Dr. Reddy's Laboratories Limited | ANDA | View NDC → |
| 1 mcg | Oral | Marksans Pharma Limited | ANDA | View NDC → |
| 2 mcg | Oral | Marksans Pharma Limited | ANDA | View NDC → |
| 4 mcg | Oral | Marksans Pharma Limited | ANDA | View NDC → |
| 1 mcg | Oral | Time Cap Laboratories, Inc | ANDA | View NDC → |
| 2 mcg | Oral | Time Cap Laboratories, Inc | ANDA | View NDC → |
| 4 mcg | Oral | Time Cap Laboratories, Inc | ANDA | View NDC → |
| 💊Injection | ||||
| 2 mcg/mL | Intravenous | AbbVie Inc. | NDA | View NDC → |
| 5 mcg/mL | Intravenous | AbbVie Inc. | NDA | View NDC → |
| 2 mcg/mL | Intravenous | Accord Healthcare, Inc. | NDA | View NDC → |
| 5 mcg/mL | Intravenous | Accord Healthcare, Inc. | NDA | View NDC → |
| 2 mcg/mL | Intravenous | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 5 mcg/mL | Intravenous | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 10 mcg/2 mL | Intravenous | Amneal Pharmaceuticals LLC × 2 listings | ANDA | View NDC → |
| 2 mcg/mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 5 mcg/mL | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 10 mcg/2 mL | Intravenous | Eugia US LLC × 2 listings | ANDA | View NDC → |
| 2 mcg/mL | Intravenous | West-Ward Pharmaceuticals Corp | NDA | View NDC → |
| 5 mcg/mL | Intravenous | West-Ward Pharmaceuticals Corp × 2 listings | NDA | View NDC → |
Showing 39 of 39 products — FDA National Drug Code Directory. See every product, package size and price: browse all 39 Paricalcitol NDCs →
Paricalcitol side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Paricalcitol — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Paricalcitol are death, cardiac disorder, myocardial infarction; about 91% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Paricalcitol in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Paricalcitol FDA approval history
How Paricalcitol went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Paricalcitol was first approved by the FDA in 1998 (Brand: ZEMPLAR · Abbvie); the first generic version was approved in 2011. It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Paricalcitol recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Paricalcitol recalls since July 2021.
✅No Paricalcitol recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 73710 3 dose forms · 8 strengths
-
Dose form (SCDF) Injectable Solution RxCUI 378380In current FDA listings -
Dose form (SCDF) Injection RxCUI 1736918In current FDA listingsClinical drug / strength (SCD) 1 ML paricalcitol 0.002 MG/MLRxCUI 17369311 ML paricalcitol 0.005 MG/MLRxCUI 17369192 ML paricalcitol 0.005 MG/MLRxCUI 1807896 -
Dose form (SCDF) Oral Capsule RxCUI 577314In current FDA listings
Look up RxCUI 73710 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Paricalcitol supply and shortage status
Whether Paricalcitol is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Paricalcitol brand names
Paricalcitol is sold under one brand name in the FDA directory — Zemplar. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Paricalcitol: manufacturers and labelers
11 companies list Paricalcitol products with the FDA. By number of product records, the largest are Amneal Pharmaceuticals LLC, AbbVie Inc., Bryant Ranch Prepack. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Paricalcitol drug class (RxNorm)
Paricalcitol belongs to the Vitamin D Analog class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Paricalcitol page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. AbbVie Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →